A Comprehensive Approach to Managing HER2-Positive Breast Cancer
Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine.
This activity is supported by an independent educational grant from Genentech.
Scroll to the Bottom of this Information to Begin this Course
Release date: October 3, 2017
Valid through: October 3, 2018
Topic: Breast cancer, HER2+, immunohistochemistry, in-situ hybridization, targeted treatment, shared decision-making
Estimated Time to Complete Activity: 60 minutes
Oncologists and other physicians, nurse practitioners, nurses, physician assistants, and other clinicians who specialize in oncology and management of patients with breast cancer.
This multifaceted educational program aims to educate physicians, nurse practitioners, and physician assistants about the role of molecular testing in breast cancer and implications of HER2-positivity in breast cancer. The interactive and fast-paced self-study module will allow you to respond to questions, see how your peers do, and provide expert opinion regarding personalized treatment selection and sequencing for patients with HER2-positive breast cancer, including neoadjuvant and adjuvant therapies, as well as strategies to improve patient engagement through education and shared decision-making.
The self-study module will prepare you for a live webinar, during which you will be able interact with faculty members, review cases, and ask questions. The webinar will be archived for on-demand access. After participating in the preparatory activity and webinar, you can advance to the post-test and evaluation sections and claim credit.
After participating in this educational initiative, participants will be able to:
- Utilize the updated ASCO/CAP 2013 guidelines and the most recent NCCN guidelines for breast cancer to improve detection and classification of HER2 status
- Apply current efficacy and safety data to select targeted treatments that improve outcomes for patients with HER2-positive breast cancer
- Apply current guideline-recommended neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive breast cancer
- Effectively engage patients with HER2-positive breast cancer in their healthcare by implementing effective shared decision-making strategies
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Chief, Division of Hematology/Oncology and Palliative Care
Endowed Professor of Hematology/Oncology
Department of Medicine
University of Wisconsin School of Medicine and Public Health
Ruth O’Regan, MD, is the division chief of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. She previously was the Louisa and Rand Glenn Family Chair in Breast Cancer Research at Emory University in addition to being medical director at Glenn Family Breast Center of Emory University, and director of the Breast Cancer Translational Research Program at the Winship Cancer Institute.
Nurse Practitioner, McKelvey Lung Transplant Center
Emory University Hospital
Adjunct Faculty, Nell Hodgson Woodruff School of Nursing
Kate Carlson Wrammert, MSN, ANP-BC, WHNP-BC, AOCNP, is a board-certified nurse practitioner at the McKelvey Lung Transplant Center of Emory University Hospital in Atlanta, Georgia, where she is also adjunct faculty at the Nell Hodgson Woodruff School of Nursing. Ms Wrammert sits on the Jack & Jill Late Stage Cancer Foundation’s Medical Advisory Board, and has presented more than 25 invited lectures on subjects pertaining to breast cancer. Ms Wrammert previously spent 13 years as a Nurse Practitioner at the Winship Cancer Institute of Emory University.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
- Consulting: Lilly
- Contracted Research: Oncothyreon
- No affiliations with commercial interest to disclose.
- Elizabeth Paczolt, MD, has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
Planners and Managers
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
How to Receive Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0 for Mac OSX 10.7 and above
For video playback, install the latest version of Flash or Quicktime.
|Supported Phones & Tablets: |
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above